About this research groupThis group focuses on dendritic cell vaccination. Dendritic Cell (DC) therapy represents a promising immunotherapeutic approach for the treatment of cancer. The beauty of DC therapy is that it exploits the body's own immune system to fight cancer.
AimsThe group's main aim is to keep improving their DC vaccines to reach even better clinical results.
DiscoveriesThe group is amongst the first (since 1997) investigating the potency of this approach, where DC were isolated or grown from immune cells isolated from the blood of a cancer patient. Within specialized cleanrooms, personalized DC vaccines are prepared by activating DC and loading them with tumor antigens. Subsequently, patients are vaccinated.
So far, the group has mainly focused on melanoma, a cancer of the pigmented cells of the skin. The group has treated over 350 patients until now and observed that DC vaccination is well tolerated with minimal side effects. In some patients the group has seen remarkable and long lasting remissions.